We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$644M
AUM Growth
+$56M
Cap. Flow
+$39.2M
Cap. Flow %
6.09%
Top 10 Hldgs %
67.17%
Holding
35
New
5
Increased
14
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$27M
2
FBRX icon
Forte Biosciences
FBRX
+$19.2M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$16M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$11M
5
LOXO
Loxo Oncology, Inc
LOXO
+$7.94M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$31.6M
2
BPMC
Blueprint Medicines
BPMC
+$21.7M
3
IMDZ
Immune Design Corp.
IMDZ
+$8.39M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$7.07M
5
FATE icon
Fate Therapeutics
FATE
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 78.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.78M 0.74%
50,591
+6,582
+15% +$756K
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.42M 0.53%
+60,000
New +$3.01M
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$1.11B
$3.32M 0.52%
+274,196
New +$2.93M
RGLS
29
DELISTED
Regulus Therapeutics
RGLS
$3.23M 0.5%
27,324
+22,132
+426% +$3.69M
OREX
30
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.13M 0.33%
734,976
– –
ANTH
31
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.63M 0.25%
1,006,507
-2
-0% -$4
FLNA
32
Filana Therapeutics
FLNA
$46.4M
$1.34M 0.21%
325,508
+1
+0% +$5
FATE icon
33
Fate Therapeutics
FATE
$293M
$1.27M 0.2%
391,386
-1,553,859
-80% -$5.95M
IMDZ
34
DELISTED
Immune Design Corp.
IMDZ
– –
-1,233,976
Closed -$8.39M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2017 Portfolio in Review

As of Q2 2017, BVF Inc held 35 positions worth $644M, up 9.5% from $588M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

BVF Inc deployed $39.2M of net new capital in Q2 2017, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Forte Biosciences: 3,411 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 76% a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $31.6M trimmed.

  • BVF Inc's largest Q2 2017 buy was Forte Biosciences: 3,411 shares worth $15.4M.
  • BVF Inc added most to Array Biopharma Inc in Q2 2017, an estimated $27M increase.
  • BVF Inc's biggest Q2 2017 reduction was Cytokinetics, cutting an estimated $31.6M.
  • BVF Inc fully exited Immune Design Corp. in Q2 2017, selling an estimated $8.39M.
  • BVF Inc's ten largest holdings make up 67% of its $644M portfolio in Q2 2017.
  • BVF Inc opened 5 new positions and closed 1 in Q2 2017.
  • BVF Inc's portfolio value rose 9.5% quarter-over-quarter to $644M.

Based on BVF Inc's 13F filing for Q2 2017, filed 14 Aug 2017.